Global EditionASIA 中文双语Français
Business
Home / Business / Companies

Chinese professor shares experience in CAR-T therapy at Conference

chinadaily.com.cn | Updated: 2021-11-04 06:40
Share
Share - WeChat
Professor Zhao Weili, bottom, from Ruijin Hospital at the Shanghai Jiao Tong University School of Medicine speaks during the online session. [Photo provided to chinadaily.com.cn]

Top scholars from China and abroad met online to discuss academic developments with a focus on cutting-edge technologies contributing to global medical development and worldwide health during the 26th Asia-Pacific Bone and Marrow Transplantation Congress, which was held from Oct 14 to 17.

In the CAR-T academic session on Oct 16, international experts and scholars gave presentations and exchanged views on the role of CAR-T cell therapy in hematological tumors. Professor Zhao Weili from Ruijin Hospital of the Shanghai Jiao Tong University School of Medicine made a closing speech and shared the Chinese experience with CAR-T therapy.

Zhao discussed the treatment of two diffuse large B-cell lymphoma patients in China who received CAR-T cell therapy. Through a comprehensive presentation of patient characteristics, treatment process, adverse events management post CAR-T, and efficacy assessment, she demonstrated the outstanding efficacy of CAR-T for the treatment of lymphoma, the valuable Chinese experience in the whole process of CAR-T management, as well as current challenges and effective strategies to tackle them.

A slide from Zhao Weili's speech. [Photo provided to chinadaily.com.cn]

The Chinese case study presented by Zhao was a 57-year-old female, and the first patient enrolled in the pre-marketing clinical trial in China. She was diagnosed with Non-GCB DLBCL at Ann Arbor stage II with an IPI score of 2. After diagnosis, the patient received multiple rounds of treatment including R-CHOP, R2-ICE and R2-GDP, all of which resulted in disease progression.

Thus, she decided to try CAR-T immunotherapy. A clinical study in November 2018 used Axicabtagene Ciloleucel (Axi-Cel) to achieve a good outcome after CAR-T re-infusion, with the efficacy assessment showing partial remission by day 28 and complete remission by day 90 after re-infusion. Moreover, the patient's complete remission status has been maintained for almost 3 years.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE